IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy

Future Oncology

Volumn 10, Issue 6, 2014, Pages 937-948

  Rausch, Steffen ^a   Kruck, Stephan ^a   Stenzl, Arnulf ^a,b   Bedke, Jens ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CTLA 4; cyclophosphamide; GM CSF; IMA901; immune therapy; PD 1; renal cell carcinoma; tumor microenvironment; tumor associated antigen; tyrosine kinase inhibitor; vaccination

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CELL PROTEIN; CYCLOPHOSPHAMIDE; IMA 901; INTERLEUKIN 2; PEPTIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; IMA901 VACCINE; SUBUNIT VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR IMMUNITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY METASTASIS; NERVE CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; CARCINOMA, RENAL CELL; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

CANCER VACCINES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84903145183     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.61     Document Type: Article

References (80)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010
2. Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A. Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy. World J. Urol. 32(1), 31-38 (2014
3. Dengjel J, Nastke MD, Gouttefangeas C et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 12(14 Pt 1), 4163-4170 (2006
4. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br. J. Urol. 63(2), 128-131 (1989
5. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: The 2010 update. Eur. Urol. 58(3), 398-406 (2010
6. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J. Clin. Pharmacol. 45(8), 872-877 (2005
7. Mignogna C, Staibano S, Altieri V et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five year follow-up analysis. BMC Cancer 6, 293 (2006
8. Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer Ther. 12(6), 777-785 (2012
9. Interferon-Alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146), 14-17 (1999
10. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 1, CD001425 (2005
11. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995
12. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003
13. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11(10), 3714-3721 (2005
14. McDermott DF, Ghebremichael MS, Signoretti S et al. The high-dose aldesleukin (HD IL-2) 'SELECT' trial in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 28(15 Suppl.), Abstract 4514 (2010
15. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006
16. van der Vliet HJ, Koon HB, Yue SC et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13(7), 2100-2108 (2007
17. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010
18. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
19. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011
20. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011
21. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11, 213-244 (1993
22. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991
23. Brookman-May S, May M, Gilfrich C, Wieland WF, Burger M. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?. Expert Rev. Anticancer Ther. 10(6), 813-823 (2010
24. Wierecky J, Muller MR, Wirths S et al. Immunologic and Clin. responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006
25. Bedke J, Laske K, Feyerabend S et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur. Urol. Supplements 11(1), e76-ea (2012
26. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254-1261 (2012
27. IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma. http://clinicaltrials.gov/show/NCT01265901
28. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39(Database issue), D913-D919 (2011
29. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004
30. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat. Rev. Clin. Oncol. 6(8), 478-487 (2009
31. Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised Phase III trial. Lancet 372(9633), 145-154 (2008
32. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20, 395-425 (2002
33. Singh-Jasuja H, Toes RE, Spee P et al. Cross-presentation of glycoprotein 96-Associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191(11), 1965-1974 (2000
34. Yang JC. Vitespen: A vaccine for renal cancer?. Lancet 372(9633), 92-93 (2008
35. Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010
36. Carsberg CJ, Myers KA, Stern PL. Metastasis-Associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int. J. Cancer 68(1), 84-92 (1996
37. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61(1), 89-95 (1990
38. Amin A, Dudek A, Logan T et al. A Phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J. Clin. Oncol. 28(15 Suppl.), Abstract 4514 (2010
39. Amin A, Dudek A, Logan T et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 31(Suppl. 6), Abstract 357 (2013
40. Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT). http://clinicaltrials.gov/show/NCT01582672
41. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010
42. de Vries IJ, Bernsen MR, Lesterhuis WJ et al. Immunomonitoring tumor-specific T cells in delayed-Type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23(24), 5779-5787 (2005
43. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008
44. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007
45. Curiel TJ. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117(5), 1167-1174 (2007
46. Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14(24), 8270-8278 (2008
47. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005
48. Vacchelli E, Martins I, Eggermont A et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 1(9), 1557-1576 (2012
49. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003
50. Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69(9), 917-927 (2009
51. Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: A place in history or in the future. Postgrad. Med. J. 79(938), 672-680 (2003
52. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin. Dev. Immunol. 2011, 609579 (2011
53. Arellano M, EK Waller. Granulocyte-macrophage-colony-stimulating factor and other cytokines: As adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines. Curr. Hematol. Rep. 3(6), 424-431 (2004
54. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18(2), 226-232 (2007
55. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993
56. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000
57. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159(2), 770-776 (1997
58. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004
59. Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2(1), e22246 (2013
60. Moschella F, Torelli GF, Valentini M et al. Cyclophosphamide induces a type I interferon-Associated sterile inflammatory response signature in cancer patients' blood cells: Implications for cancer chemoimmunotherapy. Clin. Cancer Res. 19(15), 4249-4261 (2013
61. Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46(5), 2572-2577 (1986
62. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol CII 56(5), 641-648 (2007
63. Viaud S, Flament C, Zoubir M et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71(3), 661-665 (2011
64. Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161), 971-976 (2013
65. Sevko A, Sade-Feldman M, Kanterman J et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J. Invest. Dermatol. 133(6), 1610-1619 (2013
66. Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008
67. Stehle F, Schulz K, Fahldieck C et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J. Biol. Chem. 288(23), 16334-16347 (2013
68. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009
69. Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res. 22(3), 236-243 (2012
70. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011
71. Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK. Combination of sunitinib with antitumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int. J. Cancer (2013
72. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012
73. Hodi FS, O'day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
74. Yang JC, Hughes M, Kammula U et al. Ipilimumab (antiCTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007
75. Gerritsen WR,, Kwon ED,, Fizazi K et al. CA184-043: A randomized, multicenter, double-blind Phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT). Presented at: European Cancer Congress. Amsterdam, The Netherlands, 27 September-1 October 2013
76. Fife BT, Pauken KE, Eagar TN et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunother. 10(11), 1185-1192 (2009
77. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7), 1757-1766 (2010
78. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of antiPD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
79. Study of Nivolumab (BMS-936558) vs Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025). http:// clinicaltrials.gov/show/ NCT01668784
80. Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: Preparing for the future. BioDrugs 27(1), 35-53 (2013.